News

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research…

1 year ago

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated…

1 year ago

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing…

1 year ago

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases

Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesisRefined focus on…

1 year ago

Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections

First-in-human study for ETH47 to evaluate safety, tolerability, and target engagement in healthy participantsMUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE)…

1 year ago

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration RoslinCT will manufacture world’s-first CRISPR-based…

1 year ago

Crossject announces initiation of coverage by ODDO BHF

Rated “Outperform” with price target of €7.10 Analysts cite $60 million BARDA contract for Crossject’s ZEPIZURE® as validation of platform…

1 year ago

Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023

Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 Halle (Saale) / Munich,…

1 year ago

Tinley’s Files Interim Results and Announces Investor Call

Toronto, Ontario and Los Angeles, California--(Newsfile Corp. - November 28, 2023) - The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB:…

1 year ago

Delivra Health Brands and its Leading Brands Dream Water (R) and LivRelief (TM) Report Positive Adjusted EBITDA(1) for First Quarter of Fiscal 2024

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or…

1 year ago